The Massachusetts-based biotech company led by CEO Stéphane Bancel went from relative obscurity to the Wall Street spotlight when its mRNA-based COVID-19 vaccine, developed with scientists from the U.S. National Institute of Allergy and Infectious Diseases, became the first in the U.S. to start human testing last March. The vaccine’s December 2020 greenlight by the U.S. Food and Drug Administration—and its subsequent worldwide distribution—vindicates the company’s focus on using mRNA genetic material to teach the human body to fight off COVID-19. Millions have received the shot, and Moderna is ramping up production to meet continued worldwide demand.
More Must-Reads from TIME
- The 100 Most Influential People in AI 2024
- Inside the Rise of Bitcoin-Powered Pools and Bathhouses
- How Nayib Bukele’s ‘Iron Fist’ Has Transformed El Salvador
- What Makes a Friendship Last Forever?
- Long COVID Looks Different in Kids
- Your Questions About Early Voting, Answered
- Column: Your Cynicism Isn’t Helping Anybody
- The 32 Most Anticipated Books of Fall 2024
